S2 Table. Overview of the variant alleles (mutations) of the various pharmacogenes included in the genotyping panels and the respective genotype-predicted aberrant phenotypes required for gene-drug interaction (GDI) assessments.

Gene	Variant allele panel	Genotype-predicted aberrant phenotypes
CYP2D6 [1]	Non-coding variant alleles: • 2D6*3 (rs35742686) • 2D6*4 (rs3892097) • 2D6*6 (rs5030655) Reduced-function variant alleles: • 2D6*9 (rs5030656) • 2D6*10 (rs1065852) • 2D6*41 (rs29001518) Copy number analysis: • 2D6*5 (whole gene deletion) • multiplication of fully-functional alleles (2D6*1 or *2)	'Poor metabolizers' (PMs): Homozygous carriers of non-coding alleles 'Intermediate metabolizers' (IMs): Heterozygous carriers of non-coding alleles and homozygous carriers of reduced-function alleles 'Ultrarapid metabolizers' (UMs): Carriers of three or more functional gene copies
CYP2C19 [1]	Non-coding variant alleles: • 2C19*2 (rs4244285) • 2C19*3 (rs4986893/rs57081121) • 2C19*4 (rs28399504) Gain-of-function allele: • CYP2C19*17 (rs12248560)	PMs: Homozygous carriers of non-coding alleles IMs: Heterozygous carriers of non-coding alleles UMs: Hetero- or homozygous carriers of the gain-of-function allele
CYP2C9 [1]	Reduced-function alleles: • 2C9*2 (rs1799853) • 2C9*3 (rs1057910)	PMs: Homozygous carriers of CYP2C9*3 IMs: Heterozygous carriers of CYP2C9*3 and homozygous carriers of CYP2C9*2
CYP3A5 [1]	Non-coding variant allele: • CYP3A5*3 (rs776746)	Increased CYP3A5 metabolism: Hetero- or homozygous carriers of CYP3A5*1
SLCO1B1 [2]	Reduced-function allele: • 521T>C/*5 (rs4149056)	Decreased OATP1B1-mediated transport, e.g. of statins: Hetero- or homozygous carriers of the reduced-function allele
VCORK1 [3]	Increased VCORK1-sensitivity: • VKORC1*2 (rs9923231)	Low-dose warfarin responders: Hetero- or homozygous carriers of VKORC1*2

All genotyping assays were validated and had been certified by Norwegian accreditation for routine clinical use. All variant allele analyses were performed using Taqman-based realtime PCR assays.

REFERENCES:

[1] Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. Clin Pharmacol Ther. 2018; 103: 399-401.

[2] Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. British journal of pharmacology. 2009; 158: 693-705.

[3] Owen RP, Gong L, Sagreiya H, Klein TE, Altman RB. VKORC1 pharmacogenomics summary. Pharmacogenetics and genomics. 2010; 20: 642-4.